Literature DB >> 27049258

Advance in the study on p38 MAPK mediated drug resistance in leukemia.

F Gao1, W-J Liu.   

Abstract

Leukemia is a group of malignant clone diseases of hematopoietic stem cells, while drug resistance (DR) has become the primary cause of chemotherapy failure. p38 mitogen-activated protein kinase (p38MAPK) signaling pathway induces cell activation, proliferation and apoptosis in response to extracellular stimuli. Recent studies have shown that p38 MAPK signaling pathway is closely associated with DR in leukemia. The present article reviews the relationship between p38 MAPK signaling pathway and DR in leukemia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27049258

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

Review 1.  Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.

Authors:  Zahra Zandi; Bahareh Kashani; Zivar Alishahi; Atieh Pourbagheri-Sigaroodi; Fatemeh Esmaeili; Seyed H Ghaffari; Davood Bashash; Majid Momeny
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-04       Impact factor: 4.553

2.  A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling.

Authors:  Mara Salomé; Aoife Magee; Krisha Yalla; Shahzya Chaudhury; Evgenia Sarrou; Ruaidhrí J Carmody; Karen Keeshan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

3.  Activation of RSK2 upregulates SOX8 to promote methotrexate resistance in gestational trophoblastic neoplasia.

Authors:  Shaobin Wu; Mingjie Shao; Yi Zhang; Dazun Shi
Journal:  Lab Invest       Date:  2021-08-09       Impact factor: 5.662

4.  High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.

Authors:  Yuan-Feng Lin; Ing-Jy Tseng; Chih-Jung Kuo; Hui-Yu Lin; I-Jen Chiu; Hui-Wen Chiu
Journal:  J Cell Mol Med       Date:  2018-02-01       Impact factor: 5.310

Review 5.  Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity.

Authors:  Shannon Lee; Jens Rauch; Walter Kolch
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

6.  Effects of signaling pathway inhibitors on hematopoietic stem cells.

Authors:  Yuyu Jiang; Zhaofeng Xu; Na Ma; Lizhi Yin; Caiqin Hao; Jing Li
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.